Immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, are effective therapeutic agents that inhibit the immune escape of tumor cells and enhance the antitumor activity of T cells [6, 7]. This evidence concerns the gene CD274 and neoplasm.